Innovations from Nuclear Receptors

Phenex Pharmaceuticals is a drug discovery and development company focussed on the target class of nuclear receptors for the development of novel pharmaceuticals.
Phenex currently pursues two independent small molecule programs targeting nuclear receptors:

• FXR agonists for the treatment of the Metabolic Syndrome and Non-alcoholic Steatohepatitis (NASH).
• RORyt antagonists for the treatment of a range of autoimmune diseases such as Psoriasis or Rheumatoid Arthritis.

The company aims to partner these programs with a pharmaceutical company for further clinical development after clinical proof-of-concept studies.
Beyond its proprietary drug discovery programs the company has assembled a powerful platform for research on nuclear receptors. Phenex offers these assets on a fee-for-service basis to the Life Science industry under its Discovery Services unit.